tbuckley/cabot-search huggingface dataset:
A study of triple-negative breast cancer at a cancer institute in India.
Authors: M. P. Ram Prabu, V. Raina, N. K. Shukla, B. K. Mohanti, S. V. S. Deo
Journal: Journal of Clinical Oncology (2011)

e11548 Background: Triple negative breast cancer (TNBC) has been identified as an independent poor prognostic factor for survival. Data from India is lacking. The aim of this study was to compare the clinico-pathological characteristics and treatment outcomes of patients with TNBC and non-TNBC. Methods: We did a retrospective study of 636 patients with invasive breast cancer between June 2005 and July 2009 in whom estrogen receptor, progesterone receptor and Her-2Neu status were available. Event free survival (EFS) and overall survival (OS) were defined as the time period from diagnosis to occurrence of event and death respectively. Relapse, progression or metachronous breast cancer were taken as events. Chi-square/Fischer Exact test for categorical and t-test for non-categorical variables, Kaplan-Meier curves and log-rank test for survival analysis and Cox proportional hazards model for univariate and multivariate analysis were used. Results: 155(24.4%) patients had TNBC. Patients with TNBC had significantly lower median age (46.6 vs 49.8 yrs; p=0.005, 95% CI: 0.98 to 5.38) and higher proportion of high grade tumors as compared to non-TNBC group (43% vs 23.5%; p<0.0001). The proportion of premenopausal to post-menopausal women (1.2:1 vs 0.9:1; p=0.139), median tumor size (5.2 vs 5.1 cms; p=0.685,95% CI: -0.762 to 0.5), node positivity rate (61.7% vs 65.2%;p=0.5), stage distribution (2.8%, 31.8%, 47.7%, 17.7% vs 2.3%, 27.8%, 49.1%, 20.8% for Stage I, II, III and IV respectively; p=0.8) were not significantly different between TNBC and non-TNBC groups. After a median follow-up of 22 months, the 3 year EFS was significantly lower in TNBC group (60% vs 68%; log rank p=0.0362). 3 year OS was lower in TNBC group but not statistically significant (74% vs 84%; p=0.139). Age<49 yrs, higher nodal stage and larger tumor size (>5cms) but not triple negativity were significant negative prognostic factors by multivariate analysis for EFS and OS. Conclusions: TNBC is significantly associated with younger age and high grade tumors. Triple negativity was a significant poor prognostic factor by univariate analysis for EFS but not OS. This may be due to small sample size and rather short follow-up.
Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
Authors: Anas Younes, Leo Gordon, Stella Kim, Jorge Romaguera, Amanda R Copeland, Silvana de Castro Farial, Larry Kwak, Luis Fayad, Frederick Hagemeister, Michelle Fanale, John Lambert, Teresa Bagulho, Rodica Morariu-Zamfir
Journal: Blood (2009)
The Peter Principle in Cardiovascular Cell Therapy
Authors: Gaia Spinetti, Paolo Madeddu
Journal: Circulation Research (2016)

C ontroversies in stem cell therapy for cardiovascular regeneration/repair highlight the need to go back to the root of the problem and analyze the reasons for the current ideological stagnation.Technological advancements are often advocated to overcome a scientific stalemate.However, technology does not suffice without a clear physiological understanding of stem cell biology as a component of the general feedback response to injury.This viewpoint opines that endogenous mechanisms of repair are incompletely understood, and more research is needed in humans and experimental models to dissect the role of stem cells in the pathogenesis of cardiovascular diseases. Picking the Low-Hanging FruitIn 1969, Peter and Hull formulated a management principle stating that anything that is used in more challenging applications will finally fail.Examples of medical theories that failed in translation are countless.This phenomenon can be interpreted in 2 opposite ways: (1) something was wrong in the initial judgment or (2) validation and exploitation were misaligned from the original theory.Furthermore, controversies are often unproductive, that is, during the flat stage of postdiscovery S-curve, experts are mainly occupied in defending or attacking the theory, with the result that they are only picking the low-hanging fruit from the science tree.Not surprisingly, a rapid flourishing of new ideas occurs immediately after the disappearance of imposing leaders.
Unraveling STAT Signaling in NPM/ALK-Induced Lymphoma: STAT3 but Not STAT5 Is Required for Lymphomagenesis in a Bone Marrow Transplantation Model Using Conditional Knockout Mice.
Authors: Tobias Dechow, Elisa Amon, Cornelius Miething, Rebekka Grundler, Nicole Schatz, Marcus Kremer, Wolfgang Reindl, Ingo Ringshausen, Christian Peschel, Justus Duyster
Journal: Blood (2009)
Rare Case of an Immunocompetent Patient with Multicentric Castleman's Disease and Pure Nodal Kaposi's Sarcoma Achieving Complete Remission Using Rituximab and Liposomal Doxorubicin
Authors: Damien Hansra, Jorge Antunez de Mayolo, Arfa Malik, Lisellet Morin, Abraham Jaguan, Jason Kosove, Maureen Cioffi-Lavina
Journal: Blood (2016)
Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32.
Authors: E. P. Mamounas, S. J. Anderson, T. B. Julian, D. N. Krag, D. Weaver, T. Ashikaga, S. P. Harlow, N. Wolmark
Journal: Journal of Clinical Oncology (2011)

86 Background: In NSABP B-32 5611 women with invasive breast cancer were randomly assigned to SLNB plus axillary dissection or SLNB alone. Permanent pathologic assessment of SLNs at participating sites was designed to identify all macrometastases &gt;2 mm (slicing SLNs at approximately 2.0 mm intervals, embedding all slices in paraffin tissue blocks, and examining one H&amp;E-stained slide from each block). Routine use of IHC or deeper sectioning was prohibited. SLN paraffin tissue blocks from negative SLNs were later evaluated centrally for occult metastases deeper in the blocks. In this report we examine the effect of this detailed assessment on the FNR of SLNB. Methods: Routine and cytokeratin IHC stains were used at two widely spaced additional levels. Occult metastases were detected in 616 of 3884 pts (15.9%) with initially negative SLNs; 69.8% had isolated tumor-cells, 27.9% micrometastases, and 2.3% macrometastases (Weaver D, et al: N Engl J Med, 2011). Results: Previously reported FNR in B-32 was 9.8% (75 of 766 pts). Information on additional pathologic assessment was available on 72 of these 75 pts and revealed occult metastases in 23 pts (31.9%). Of those 23 pts, 14 had isolated tumor cells (61%), 7 had micrometastases (30%), and 2 had macrometastases (9%) in the SLN. Including the information from the additional pathologic assessment, the FNR of SLNB in B-32 was reduced to 6.4% (49 of 763 cases). This 35% reduction in FNR was statistically significant (p&lt; 0.001). Among the 23 FN SLNs with occult metastases, the number of positive non-SLNs was 1 in 16 pts, 2 in 2 pts, 3 in 2 pts, 4 in 2 pts, and 6 in 1 pt. Conclusions: In the B-32 trial, more detailed assessment of the SLNs with deeper sectioning and IHC staining would have significantly reduced the FNR of SLNB by about one-third. However, this reduction would have come at the expense of a 16% increase in the rate of axillary dissection by taking occult metastases into account. Supported by NCI: U10-CA-12027, U10-CA-37377, U10-CA-69974, U10-CA-69651; and ARRA ROI CA 74137.
Defining “cisplatin ineligible” patients with metastatic bladder cancer.
Authors: M. D. Galsky, N. M. Hahn, J. E. Rosenberg, G. Sonpavde, W. K. Oh, R. Dreicer, N. J. Vogelzang, C. N. Sternberg, D. F. Bajorin, J. Bellmunt
Journal: Journal of Clinical Oncology (2011)

238 Background: Cisplatin-based chemotherapy is standard first-line treatment for patients (pts) with metastatic urothelial carcinoma (UC). However, a large proportion of pts with UC are considered “unfit” for cisplatin, leading to clinical trials designed specifically for cisplatin-ineligible pts, with substantial variability in eligibility criteria. A clear and consistent definition of pts “unfit” for cisplatin-based therapy will aid in the development of standard eligibility criteria. Methods: We assembled a panel of GU medical oncologists and followed a three-fold approach. First, we surveyed 120 international GU medical oncologists. Subsequently, we reviewed the literature regarding ‘cisplatin ineligibility‘ in solid tumors. Finally, the panel reconciled the survey results and available literature and generated a consensus definition. Results: Responses were received from 65/120 (54%) of those surveyed. The survey results are shown in the Table . Reconciling the survey results with the available literature, the panel recommended the following be used to consistently define pts with metastatic UC “unfit” for cisplatin-based chemotherapy for clinical trial purposes: (1) ECOG performance status of 2 and/or (2) creatinine-clearance &lt; 60 ml/min and/or (3) CTCAE Gr ≥ 2 hearing loss and/or (4) CTCAE Gr ≥ 2 neuropathy. Conclusions: Substantial variability exists in investigators' definitions of pts with metastatic UC “unfit” for cisplatin. A consensus definition is proposed for standardization of eligibility criteria. [Table: see text] No significant financial relationships to disclose.
Clinical Significance of FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia Who Underwent Allogeneic Bone Marrow Transplantation.
Authors: Je-Jung Lee, Yu-Ra Lee, Hee-Nam Kim, Nan-Young Kim, Kyeong-Soo Park, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim
Journal: Blood (2004)
Treating chronic hepatitis in Asian and Pacific Island populations: A comparison of program costs according to current treatment guidelines.
Authors: Monica Cristina Robotin, Yumi Patton, Melanie Q Kansil, Jacob George, Andrew G Penman
Journal: Journal of Clinical Oncology (2012)

193 Background: Hepatitis B (HBV) infection is endemic in many Asian and Pacific Island countries, with 25-40% of chronic hepatitis B (CHB) patients developing cirrhosis or hepatocellular cancer (HCC). Increased migration from high HBV prevalence countries leads to Vietnamese-born Americans and Australians 11-13 times more likely to develop HCC than other groups. As antiviral therapy is more cost-effective than HCC screening, we developed a program of hepatitis B screening, monitoring and treatment targeting high–risk populations in Sydney aged &gt;35 years (the median age for HBeAg sero-conversion in Asian populations). Here we compare estimated program costs using guidelines for HBV treatment in hepatitis B e antigen negative populations. Methods: Using a Markov model, we modelled CHB disease progression and management costs using guidelines published by the American, European and Asian Pacific Associations for the Study of Liver Disease (AASLD, EASL and APASL) and algorithms created by US hepatology experts and our B Positive program, using different levels of alanine aminotransferase (ALT) for treatment initiation. We factored in costs for CHB screening and surveillance for liver damage provided by specialists and/or primary care providers, including CHB and HCC treatment, individualised by viral load and ALT levels. Costs were discounted by 5% and calculated in Australian dollars (AUD); incremental costs used AASLD guidelines as a baseline. Results: Assuming a 25% enrolment in our target population of patients with CHB in South West Sydney followed up for 50 years, total program costs would amount to 9,205,680 AUD. Using AASLD guidelines, estimated cost would amount to 6,344 AUD per patient. APASL guidelines lead to a 132% cost rise, the B Positive program costs 152% more, while the US algorithm and EASL are associated with a 221% cost increment to achieve the equivalent cost/QALY. Conclusions: While the AASLD guidelines appear to be the least costly, uncertainties about “ideal” ALT and viral load levels for treatment initiation and the extent of the benefit conferred in terms of HCC cases averted will need to be resolved to inform large-scale prevention programs.
Expression of CXCR4 and CXCR7 Receptors for Stromal Derived Factor-1 (SDF- 1) Is Differently Regulated in Human Rhabdomyosarcomas (RMS): The Biological Consequences
Authors: Maciek Tarnowski, Radoslaw Maksym, Ryan Reca, Mariusz Z Ratajczak, Magdalena Kucia
Journal: Blood (2008)
Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML)
Authors: Patrick Halliday, Alysia Bosworth, Can-Lan Sun, Tongjun Kang, Lindsey Hageman, Liton Francisco, Stephen J. Forman, Ravi Bhatia, Smita Bhatia
Journal: Blood (2013)
Absence of Association Between TNF α Polymorphysm and Cerebral Large Vessel Abnormalities in Adults with Sickle Cell Anemia
Authors: Perla Vicari, Gisele Sampaio Silva, Maria A E Noguti, Faustino Moreira Neto, Normelia Jesus Santos, Ayrton Roberto Massaro, Maria Stella Figueiredo
Journal: Blood (2008)
Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.
Authors: Anton Hagenbeek, Luis Fayad, Vincent Delwail, Jean Francois Rossi, Eric Jacobsen, Kazimierz Kuliczkowski, Brian K Link, Lauren Pinter-Brown, John Radford, Andrzej Hellmann, Eve Gallop-Evans, Ira Gupta, Michael Arning, Kamilla Begtrup, Martin Schultz, Bo Bang, Charlotte A Russell, Myron S Czuczman
Journal: Blood (2009)
The Vitamin B Requirement of Man
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Authors: Gerald F. Watts, Dick C. Chan, Ricardo Dent, Ransi Somaratne, Scott M. Wasserman, Rob Scott, Sally Burrows, P. Hugh R. Barrett
Journal: Circulation (2016)

Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations. Evolocumab is under investigation for its effects on cardiovascular outcomes in statin-treated, high-risk patients. The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains to be fully evaluated. Stable isotope tracer kinetics can effectively elucidate the mode of action of new lipid-regulating pharmacotherapies.We conducted a 2-by-2 factorial trial of the effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (420 mg every 2 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apoB), intermediate-density lipoprotein-apoB, and LDL-apoB in 81 healthy, normolipidemic, nonobese men. The kinetics of apoB in these lipoproteins was studied using a stable isotope infusion of D3-leucine, gas chromatography/mass spectrometry, and multicompartmental modeling.Atorvastatin and evolocumab independently accelerated the fractional catabolism of VLDL-apoB (P<0.001 and P.032, respectively), intermediate-density lipoprotein-apoB (P=0.021 and P=.002, respectively), and LDL-apoB (P<0.001, both interventions). Evolocumab but not atorvastatin decreased the production rate of intermediate-density lipoprotein-apoB (P=0.043) and LDL-apoB (P<0.001), which contributed to the reduction in the plasma pool sizes of these lipoprotein particles. The reduction in LDL-apoB and LDL-cholesterol concentrations was significantly greater with combination versus either monotherapy (P<0.001). Whereas evolocumab but not atorvastatin lowered the concentration of free PCSK9, atorvastatin lowered the lathosterol/campesterol ratio (a measure of cholesterol synthesis/absorption) and apoC-III concentration. Both interventions decreased plasma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or measures of insulin resistance.In healthy, normolipidemic subjects, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerating their catabolism. Reductions in intermediate-density lipoprotein and LDL production also contributed to the decrease in LDL particle concentration with evolocumab by a mechanism distinct from that of atorvastatin. These kinetic findings provide a metabolic basis for understanding the potential benefits of PCSK9 monoclonal antibodies incremental to statins in on-going clinical end point trials.URL: http://www.clinicaltrials.gov. Unique identifier: NCT02189837.
Management of hepatitis C virus infection in the Asia-Pacific region: an update
Authors: Seng Gee Lim, Alessio Aghemo, Pei-Jer Chen, Yock Young Dan, Edward Gane, Rino Gani, Robert G Gish, Richard Guan, Ji Dong Jia, Kieron Lim, Teerha Piratvisuth, Samir Shah, Mitchell L Shiffman, Frank Tacke, Soek Siam Tan, Tawesak Tanwandee, Khin Maung Win, Cihan Yurdaydin
Journal: The Lancet. Gastroenterology & hepatology (2016)
Sentinel lymph node biopsy in breast cancer: The role of day surgery and local anesthetic approach.
Authors: F. Ricci, T. Scala, M. Dorkin, L. G. Capuano, P. Di Legge, M. Sacchi, M. Valleriani, R. Salvatori, C. De Masi, A. Violante, A. Pacchiarotti, M. Natali
Journal: Journal of Clinical Oncology (2011)

e11575 Background: Sentinel lymph-node biospy (SLNB) is widely used in the management of breast cancer patients without axillary metastases. Methods: From Jan.1st 2006 through Dic. 31st 2010 we performed 244 SLNB at St. M. Goretti Hospital. Mammary carcinoma was diagnosed as malignant by aspiration citology and/or biospy. In all cases with positive citology, we performed at the same time quadrantectomy and SLNB. All patients underwent pre-operative lymphoscintigraphy with intradermal pericicatritial and/or periareola injection of 55-75 MBq (2mi Ci) 99Tc colloidal albumin particles 50-80 nm size range, in 0,1-0,2 ml saline solution. We never used vital blue dye. All patients underwent surgical treatment 4-12 h. later. We performed SLNB and quadrantectomy in day-surgery (DS) and local anaesthesia (LA). Axillary incision was 3-4 cm. This study was approved by an ethics committee, was discussed with all patients and informed consent was obtained. Object of study is to investigate the validity of this procedure. Results: Four patients underwent pre-operative lymphoscintigraphy the radiotracer did not show any sentinel lymph-node (SLN), we performed axillary dissection. Three cases showed axillary isolated tumor cells (ITC). Fourteen micrometastases. Twenty-seven macrometastases. One case of negative SLN, was positive a second palpable lymph node. One case showed a double SLN in the axilla and internal mammary chain, only the internal mammary node was positive. The SLN identification rate was 99%. After surgery we distributed a questionary to the patients about the acceptability of this approach. Conclusions: The results archieved are extremely accurate. This procedure is safe, well accepted by patients ( 99%), reported better quality of life. The oncological results are absolutely reliable. As regards hospital logistics, operations in DS and LA can be easily managed, leading to a significant cost reduction 42.15% less expensive than the same operation performed under general anaesthesia.
Bone Marrow-Derived Mesenchymal Stem Cells Overexpressing Akt1 Protect Against ConA-Induced Liver Injury in Mice
Authors: Lukun Zhou, Shuang Liu, Chuanyi M. Lu, Jianfeng Yao, Yuyan Shen, Xin Yang, Sizhou Feng, Mingzhe Han
Journal: Blood (2014)
Developments of treatment of advanced intrahepatic cholangiocarcinoma: An analysis of systemic and local therapy modes in 57 patients.
Authors: Patrick Stuebs, Peter Habermann, Benjamin Garlipp, Kerstin Schuette, Kathrin Zierau, Hans Lippert, Joerg Fahlke
Journal: Journal of Clinical Oncology (2012)

346 Background: Treatment of advanced CCC remains difficult. Sophisticated therapy of individual locations is essential due to differing biological characteristics. Apart from recent systemic therapeutic approaches, combined treatments using, among others, locally ablative procedures offer chances of extended life expectancy. Methods: This analysis is based on a phase II study on treatment of advanced BTC (biliary tract cancer) with gemcitabine/docetaxel(G/D) in 79 patients (pts).Observing purely intrahepatic CCC, omitting Klatskin tumors, modes of therapy were advanced further. In addition to local ablation by TACE (TA) systemic therapy was modified using Gemcitabine/Oxaliplatin(G/O). TACE could only be employed initially in purely intrahepatic inoperable findings. Treatment was later adjusted using local brachytherapy followed by intraarterial chemotherapy with 5-FU (AL + i.a.). A retrospect data analysis of 57 pts diagnosed with advanced intrahepatic CCC was deployed after collecting cases prospectively. A matched pair analysis in relation to data from systemic treatment was performed. Ultimately, 5 groups were formed: 1- 12 pts being treated with TACE only (TA); 2- 15 pts receiving TACE initially followed by systemic therapy of progressive disease (TA+G/D); 3- 11 pts receiving G/D; 4- 14 pts receiving G/O; 5- 5 pts receiving AL+i.a. Treatment continued until either disease progressed or inacceptable side effects occurred. Results: Median time of survival in the TA group was 4.2 months, TA+G/D 20.1 months, G/D 8.5 months and G/O 15.0 months. Currently no conclusive data has been obtained in the AL+i.a. group, yet. Median time to tumour progress was 2.1 months in TA, 5.1 months in TA+G/D, 3.5 months in G/D and 7.7 months in G/O. In the G/O group a case of secondary respectability occurred. Results were achieved with an acceptable toxicity profile and satisfactory quality of life. Conclusions: When the advanced intrahepatic CCC, voiding Klatskin tumours, are limited to the liver and do not offer the possibility of surgical intervention, a combination of treatments should be commenced. Improved systemic protocols can additionally achieve extended time of survival.